Drug‐drug interactions in pharmacologic management of gastroparesis. Issue 11 (8th June 2015)

• Record Type: Journal Article
• Authors: Youssef, A. S.; Parkman, H. P.; Nagar, S.
• Is Part Of: Neurogastroenterology & motility. Volume 27:Issue 11(2015:Nov.)
• Page Start: 1528
• Page End: 1541
• Publication Date: 2015-06-08
• Subjects: Gastrointestinal system -- Motility -- Periodicals; Gastrointestinal system -- Innervation -- Periodicals; 616.33
• DOI: 10.1111/nmo.12614
• Languages: English
• ISSNs: 1350-1925

Abstract

<abstract abstract-type="main" id="nmo12614-abs-0001"> <title>Abstract</title> <sec id="nmo12614-sec-0001" sec-type="section"> <title>Background</title> <p>Gastroparesis is a disorder characterized by delayed gastric emptying due to chronic abnormal gastric motility. The treatment of the disease often entails the co‐administration of several classes of pharmacological agents. These agents may be metabolized via the same pathway. Inhibition or induction of a shared metabolic pathway leads to change in the systemic levels of prescribed drugs, possibly leading to undesired clinical outcomes.</p> </sec> <sec id="nmo12614-sec-0002" sec-type="section"> <title>Purpose</title> <p>This review discusses different pharmacological treatment for gastroparesis patients and describes the potential for drug‐drug interactions (DDIs) in some of the combinations that are currently used. Prokinetic agents such as metoclopramide and domperidone are the cornerstone in treatment of gastroparesis. Antiemetic agents such as promethazine and ondansetron are frequently administered to gastroparesis patients to reduce nausea and vomiting. Gastroparesis is prevalent in diabetic patients and therefore antidiabetic agents are also prescribed. Many of these co‐administered drugs are metabolized <italic>via</italic> common drug metabolizing enzymes and this can trigger potential DDIs. The scientific literature was reviewed from the years 1975–2014 for original research articles and reviews that evaluated DDIs in gastroparesis. Many commonly prescribed combinations were predicted to cause potential DDIs in gastroparesis patients. This review will help inform about potential hazardous combinations. This information will hopefully lead to less adverse effects and more successful gastroparesis management.</p> </sec> </abstract>